Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Sarcoidosis
Interventions
Rituximab
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Sarcoidosis; Antimycobacterial Therapy
Interventions
Levofloxacin, Ethambutol, Azithromycin, Rifampin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Albany, New York • Cincinnati, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced May 22, 2026, 1:08 AM EDT
Not listed No phase listed Observational
Conditions
Sarcoidosis
Interventions
observation
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 100 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced May 22, 2026, 1:08 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers
Conditions
Pulmonary Sarcoidosis
Interventions
nicotine patch
Drug
Lead sponsor
Elliott Crouser MD
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Pulmonary Sarcoidosis
Interventions
Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Pulmonary Disease, Oropharyngeal Disease, Lymphangioleiomyomatosis, Pulmonary Fibrosis, Asthma, Sarcoidosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Sarcoidosis, Pulmonary Arterial Hypertension
Interventions
Bosentan, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
New York, New York • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Sarcoidosis
Interventions
Riociguat, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Barrett Esophagus, Esophageal Dysplasia, Esophageal Neoplasm, Esophageal Stenosis, Bronchial Neoplasm, Stenosis of Bronchus or Trachea
Interventions
truFreeze Spray Cryotherapy
Device
Lead sponsor
US Endoscopy Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
16
States / cities
La Jolla, California • Denver, Colorado • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Sarcoidosis-associated Pulmonary Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Pulmonary Sarcoidosis
Interventions
CMK389, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Birmingham, Alabama • Gainesville, Florida • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Respiratory Bronchiolitis Associated Interstitial Lung Disease, Desquamative Interstitial Pneumonia, Cryptogenic Organizing Pneumonia, Acute Interstitial Pneumonitis, Idiopathic Lymphoid Interstitial Pneumonia, Idiopathic Pleuroparenchymal Fibroelastosis
Interventions
Bardoxolone methyl, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Sarcoidosis
Interventions
all subjects will receive maraviroc 300mg orally twice a day for 6 weeks, Bronchoscopy with bronchoalveolar lavage, venipunctures, Skin biopsy
Drug · Procedure
Lead sponsor
Kevin F. Gibson
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Sarcoidosis
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma, Recurrent Respiratory Papillomatosis
Interventions
CryoSpray Ablation
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available
Conditions
Sarcoidosis, Pulmonary
Interventions
Atorvastatin, Placebo Oral Tablet
Drug · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Sarcoidosis, Pulmonary Hypertension
Interventions
Observation
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced May 22, 2026, 1:08 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
Conditions
Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Pulmonary Sarcoidosis
Interventions
Mycophenolate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Sarcoidosis
Interventions
Habitrol, Placebo to Habitrol
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Interventions
Semaglutide Pen Injector
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Sarcoidosis, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 22, 2026, 1:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
Conditions
Sarcoidosis, SARS-CoV2 Infection, Vaccine Response Impaired
Interventions
Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced May 22, 2026, 1:08 AM EDT
Conditions
Pulmonary Sarcoidosis
Interventions
Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo
Biological
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Northridge, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced May 22, 2026, 1:08 AM EDT